Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0151814 (coronary occlusion)
 3,687 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The ability of intravenous or oral bepridil to reduce infarct size was studied in the rat submitted in situ to coronary-artery ligation. Infarct size was measured by planimetry of serial 8-micron sections at known intervals 48 hr after left-coronary-artery ligation. Succinate dehydrogenase activity (nitroblue tetrazolium stain) was used as an index of tissue viability. Bepridil was administered either intravenously (5 mg/kg) 15 min before (pretreatment) or 10 min after (post-ligation treatment) coronary-artery ligation, or orally (50 mg/kg per day) for 8 days before coronary ligation. Intravenous bepridil pretreatment reduced infarct size by more than 30%. This reduction was accompanied by a better preservation of the myocardial content of adenine nucleotides and a reduction in lactate accumulation. Intravenous post-ligation treatment and chronic oral treatment induced a reduction in infarct size similar to the one observed with intravenous preligation treatment. Thus, bepridil is equipotent in reducing infarct size whether the drug is administered intravenously before or after coronary-artery occlusion, or orally before coronary occlusion.
 ...
PMID:Reduction of myocardial infarct size in rats under the effect of bepridil. 387 3

1. The effects of bepridil, certain properties of which suggest antagonism of calcium flux, were studied: 1.1. On arterial blood pressure and heart rate in unanesthetized dogs. 1.2. On coronary and systemic hemodynamics in anesthetized dogs. 1.3. On regional blood flow (R.B.F.) in the myocardium of anesthetized dogs either normal or experimentally ischemic from temporary and/or permanent coronary occlusion. 2. Bepridil in unanesthetised dogs does not cause any significant change in heart rate or systolic blood pressure. Both the mean and diastolic blood pressures increase at the end of the observation period 20 minutes after the second injection. 3. In contrast, bepridil in anesthetized dogs induces a fall in peripheral resistance together with a drop in arterial blood pressure without any alteration in cardiac output. Both heart rate and contractile force are decreased while coronary flow is increased. 4. In models of localized transitory myocardial ischemia, bepridil (1 mg . kg-1 I.V.) induces a general increase in absolute R.B.F., particularly causing a favourable redistribution of coronary blood to the endocardium in ischemic areas, as evidenced by the improved endocardium/epicardium irrigation ratio. These favourable effects disappear when the dose of bepridil (3 mg . kg-1) used in this a preparation induces a marked drop in blood pressure and consequently a fall in coronary perfusion. 5. In models of localized permanent myocardial ischemia, bepridil has no effects either on R.B.F. in healthy or ischemic areas, or on the endocardium/epicardium irrigation ratios in these two types of areas.
 ...
PMID:[Bepridil: hemodynamic and coronary effects on normal and/or ischemic myocardium in dogs (author's transl)]. 697 Aug 58